Cullinan Therapeutics, Inc. (CGEM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Cullinan Therapeutics announced Q1 2026 financial results on May 7, 2026, triggering disclosure requirements under Item 2.02 of Form 8-K.
The filing provides minimal substantive detail, with the full earnings announcement relegated to the press release (Exhibit 99.1) that is furnished but not filed, limiting regulatory liability for the company.
This is a routine quarterly earnings announcement with no indication of material agreements, leadership changes, or other significant corporate events beyond standard financial reporting.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-10

Cullinan Therapeutics reported its financial results for the year ended December 31, 2025, which could provide investors with insight into the company's recent performance and financial health.
The earnings release may contain information on key financial metrics, such as revenue, earnings, and guidance, which could help investors assess the company's current standing and future prospects.
Investors should closely review the details of the 8-K filing, including any material agreements, leadership changes, or other significant events, as these could have an impact on the company's valuation and investment outlook.

Other reports for Cullinan Therapeutics, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.